Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
about
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeInnate and Adaptive Immune Response in Fabry DiseaseInvariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer ComorbidityA self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.Glycolipid activators of invariant NKT cells as vaccine adjuvants.CD4(+) T cell plasticity engenders robust immunity in response to cytokine therapy.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells.Trial watch: Dendritic cell-based interventions for cancer therapy.iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.
P2860
Q28087485-043E3E6B-80B4-41B3-A032-A6B7D2FE2383Q35800976-0DCD1D29-5D90-4585-8815-F5A2068E65C2Q36076707-C6F126E6-AB50-4468-A54A-BA67C3CEB5A3Q38418416-C4215B09-1F31-44AB-B20F-B2C1C33D6BC3Q38885794-5F8C083C-A02B-4BA4-AD0C-D7E2738DD831Q39833956-3D8B585D-81AC-4853-999B-E181AD007D59Q41139823-0C226A7A-77D0-4DFF-8293-A9CCBE44F12AQ42270075-8E3DEBB3-EB53-4F36-B04A-8E74BC0B9887Q42867339-6AF8CAD8-E4EF-4F2B-BBEA-D6BCD33A210FQ43032177-B4C0E88A-475A-4F32-B261-17C116A1BD5EQ50481937-BCAABE44-C3EA-441B-8059-E15AD6DA066A
P2860
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
@en
type
label
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
@en
prefLabel
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
@en
P2860
P356
P1433
P1476
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
@en
P2093
Martin K Hunn
P2860
P304
P356
10.4161/ONCI.23789
P577
2013-04-01T00:00:00Z